NASD · Healthcare · Medical Devices · USA
Insulet Corp is a mid cap company (market value between $2 billion and $10 billion) in the Medical Devices industry.
Insulet Corp develops, manufactures, and sells tubeless insulin infusion devices for people requiring insulin therapy to manage diabetes through its Omnipod platform. The company also produces delivery pods for Amgen's Neulasta Onpro kit. Insulet's products are available internationally and sold through wholesalers, distribution partners, and directly to consumers.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Insulet Corp stock.
Fairly valued: intrinsic value $136.50 per share, market price $141.96, margin of safety -4.0% (as of 2026-10-19).
Discounting its cash flows at 9.8% (average of 3 methods) values the shares at $136.50; the price of $141.96 is 4% above that value, and 75% of that value comes from beyond year five.
Leak Score: 71/100 on 12 of 12 signals (Clear Leak).
17 more funds hold it; the full list is part of the paid plan.
All 142 Medical Devices stocks
16 more in this industry show a wider margin of safety.
PODD is fairly valued (as of the 2026-10-19 close). Discounting its cash flows at 9.8% (average of 3 methods) values the shares at $136.50; the price of $141.96 is 4% above that value, and 75% of that value comes from beyond year five.
$136.50 per share (as of the 2026-10-19 close), against a market price of $141.96. That is a margin of safety of -4.0%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
71 out of 100, which we rate "Clear Leak", on 12 of 12 value investing signals.